New Op-Ed: Here’s How the Blue Tsunami Will Turn the Healthcare Tide
In my latest MedPage Today column, I look at what the 2026 midterms mean for health policy in 2027 and 2028. Incoming Democrats will soon learn that getting things done is much harder than winning.
FDA Matters provides short-form analysis of FDA policy and regulatory issues. We know you are busy, so we publish 1 to 2 columns per week, each a 3-5 minute read.
FDA Matters does not report the news….we provide analysis of what’s behind the news.
FDA Matters advocates for a more effective, efficient, and fair FDA.
FDA Matters has been featured in:
Public Health and the Midterm Elections– A Field Guide
Tomorrow is Election Day. If you haven’t already, please vote. With so many races predicted to be close, your vote matters more than ever. Over the last 20 months, the Trump Administration has proven hostile to policies and programs generally favored by the public…
Can the Midterms Save Vaccines? Don’t Count on It.
In a new MedPage Today op-ed, Steven Grossman and Michael Miller, MD, look past the November midterms to what vaccine advocates should expect in 2027. Pro-vaccine coalitions made real gains this year, coordinating legal challenges to the reshaped ACIP and pushing back…
Leading FDA Is an Impossible Job Right Now. Heidi Overton Could Still Do It Well.
In a new MedPage Today op-ed, Steven Grossman explains why he supports Heidi Overton, MD, PhD, the administration’s nominee for FDA commissioner. At her Senate HELP Committee confirmation hearing, Overton kept to a clear principle: anything the FDA has deemed safe and…
Chairman Cassidy: Please Ask Dr. Overton About FDA Decision-Making
With President Trump’s nomination of Dr. Heidi Overton as FDA Commissioner and the pending confirmation hearing, it’s worth asking for clarification about what qualifications are required to meet the weighty responsibilities of the position. Are there any…
The FDA’s Century-Long Campaign to Assure Safe Manufacturing (Part 2)
A Larger Context for Readers Monitoring FDA’s Review of Unapproved Peptide Drugs For more than a century, FDA has been working towards ensuring that drugs are consistently manufactured at scale to FDA standards. As a result, consumers can be largely assured of drugs…
The FDA’s Century-Long Campaign to Assure Safe Drug Manufacturing (Part 1)
Initial FDA approval gets all the glory in the world of drugs and biologics. However, that approval has limited value if patients cannot rely upon receiving the original FDA-approved drug product (or an FDA-approved generic or biosimilar). For over one hundred years,…